{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '131', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.3', 'Appendix 3: Adverse Events: Definitions and Procedures for Recording,', 'Evaluating, Follow-up, and Reporting', '10.3.1', 'Definition of AE', 'AE definition', 'An AE is any untoward medical occurrence in a clinical study participant, temporally', 'associated with the use of study intervention, whether or not considered related to the', 'study intervention.', 'NOTE: An AE can therefore be any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally', 'associated with the use of a study intervention.', 'NOTE: For purposes of AE definition, study intervention (also referred to as', \"Sponsor's product) includes any pharmaceutical product, biological product, vaccine,\", 'diagnostic agent, or protocol specified procedure whether investigational or marketed', '(including placebo, active comparator product, or run-in intervention), manufactured', 'by, licensed by, provided by, or distributed by the Sponsor for human use in this', 'study.', 'Events meeting the AE definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or', 'other safety assessments (eg, ECG, radiological scans, vital signs measurements),', 'including those that worsen from baseline, considered clinically significant in the', 'medical and scientific judgment of the investigator.', 'Exacerbation of a chronic or intermittent pre-existing condition including either an', 'increase in frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study intervention administration even', 'though it may have been present before the start of the study.', 'Note: Congenital disorders (eg, present from birth) not detected or diagnosed prior to', 'study intervention administration do not qualify for reporting as AE.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study', 'intervention or a concomitant medication.', 'For all reports of overdose (whether accidental or intentional) with an associated AE,', 'the AE term should reflect the clinical symptoms or abnormal test result. An overdose', 'without any associated clinical symptoms or abnormal laboratory results is reported', 'using the terminology \"accidental or intentional overdose without adverse effect.\\'', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '132', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Events NOT meeting the AE definition', 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that', 'leads to the procedure is the AE.', 'Situations in which an untoward medical occurrence did not occur (social and/or', 'convenience admission to a hospital).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Surgery planned prior to informed consent to treat a pre-existing condition that has', 'not worsened.', 'Refer to Section 8.4.6 for protocol-specific exceptions.', '10.3.2', 'Definition of SAE', 'If an event is not an AE per definition above, then it cannot be an SAE even if serious', 'conditions are met.', 'An SAE is defined as any untoward medical occurrence that, at any dose:', 'a. Results in death', 'b. Is life-threatening', 'The term \"life-threatening\" in the definition of \"serious\" refers to an event in which', 'the participant was at risk of death at the time of the event. It does not refer to an', 'event, which hypothetically might have caused death, if it were more severe.', 'c.', 'Requires inpatient hospitalization or prolongation of existing hospitalization', 'Hospitalization is defined as an inpatient admission, regardless of length of stay, even', 'if the hospitalization is a precautionary measure for continued observation. (Note:', 'Hospitalization for an elective procedure to treat a pre-existing condition that has not', 'worsened is not an SAE. A pre-existing condition is a clinical condition that is', \"diagnosed prior to the use of an MSD product and is documented in the participant's\", 'medical history.', 'd. Results in persistent or significant disability/incapacity', \"The term disability means a substantial disruption of a person's ability to conduct\", 'normal life functions.', 'This definition is not intended to include experiences of relatively minor medical', 'significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}